Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.91% is 103% above its 5-year average of 8.84%, near the high end of its 5-year range (0.18%–21.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.77% below its 12-month average of 19.63%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.91%.
DEBT TO ASSETS RATIO
17.91%
DEBT TO ASSETS RATIO AVG TTM
19.63%
DEBT TO ASSETS RATIO AVG 3Y
11.99%
DEBT TO ASSETS RATIO AVG 5Y
8.84%
DEBT TO ASSETS RATIO AVG 10Y
15.83%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-8.77%
CURRENT VS 3Y AVG
+49.33%
CURRENT VS 5Y AVG
+102.56%
CURRENT VS 10Y AVG
+13.13%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 575 covered companies
CURRENT VS SECTOR MEDIAN
+17810.28%
vs the sector median at left
OrthoPediatrics Corp.
Market Cap
$583.82M
Debt to Assets Ratio
17.91%
TTM Avg
19.63%
3Y Avg
11.99%
5Y Avg
8.84%
Market Cap
$598.37M
Debt to Assets Ratio
1.39%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$564.17M
Debt to Assets Ratio
0.19%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$562.72M
Debt to Assets Ratio
0.45%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.05M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$560.00M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$549.35M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$620.81M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OrthoPediatrics Corp. (KIDS) | $583.82M | 17.91% | 19.63% | 11.99% | 8.84% |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 1.39% | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $564.17M | 0.19% | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $562.72M | 0.45% | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $562.66M | 0.16% | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $560.05M | 0.00% | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $549.35M | 0.01% | N/A | N/A | N/A |
| AngioDynamics, Inc. (ANGO)vs › | $620.81M | 0.00% | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $621.12M | 0.01% | N/A | N/A | N/A |
Debt/Assets
17.9%
Debt/Equity
0.27
Current Ratio
4.78
Interest Coverage
-4.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.91% |
| 2026-03-31 | 21.16% |
| 2025-12-31 | 19.66% |
| 2025-09-30 | 20.13% |
| 2025-06-30 | 19.29% |
| 2025-03-31 | 15.56% |
| 2024-12-31 | 17.10% |
| 2024-09-30 | 16.20% |
| 2024-06-30 | 3.27% |
| 2024-03-31 | 2.87% |
| 2023-12-31 | 2.29% |
| 2023-09-30 | 0.18% |
| 2023-06-30 | 0.29% |
| 2023-03-31 | 0.20% |
| 2022-12-31 | 0.21% |
| 2022-09-30 | 0.29% |
| 2022-06-30 | 9.75% |
| 2022-03-31 | 0.34% |
| 2021-12-31 | 9.24% |
| 2021-09-30 | 9.26% |
| 2021-06-30 | 0.46% |
| 2021-03-31 | 8.65% |
| 2020-12-31 | 8.16% |
| 2020-09-30 | 0.50% |
| 2020-06-30 | 6.47% |
| 2020-03-31 | 12.18% |
| 2019-12-31 | 14.35% |
| 2019-09-30 | 33.38% |
| 2019-06-30 | 33.88% |
| 2019-03-31 | 18.98% |
| 2018-12-31 | 18.98% |
| 2018-09-30 | 33.03% |
| 2018-06-30 | 32.65% |
| 2018-03-31 | 31.54% |
| 2017-12-31 | 30.93% |
| 2017-09-30 | 67.17% |
| 2017-06-30 | 63.81% |
| 2017-03-31 | 59.22% |
| 2016-12-31 | 57.17% |
| 2016-03-31 | 43.46% |
